Miller Fisher Syndrome in the COVID-19 Era – A Novel Target Antigen Calls for Novel Treatment

Although Miller Fisher syndrome cases have been published in this coronavirus disease 2019 (COVID-19) pandemic, anti-GQ1b antibody has not been identified so far. A direct proof of association is not yet available since the exact pathophysiology is not known. Using a proof of contradiction argument,...

Descripción completa

Detalles Bibliográficos
Autores principales: Kajani, Surina, Kajani, Raheem, Huang, Chin-Wei, Tran, Tu, Liu, Antonio K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779142/
https://www.ncbi.nlm.nih.gov/pubmed/33409112
http://dx.doi.org/10.7759/cureus.12424
_version_ 1783631273321824256
author Kajani, Surina
Kajani, Raheem
Huang, Chin-Wei
Tran, Tu
Liu, Antonio K
author_facet Kajani, Surina
Kajani, Raheem
Huang, Chin-Wei
Tran, Tu
Liu, Antonio K
author_sort Kajani, Surina
collection PubMed
description Although Miller Fisher syndrome cases have been published in this coronavirus disease 2019 (COVID-19) pandemic, anti-GQ1b antibody has not been identified so far. A direct proof of association is not yet available since the exact pathophysiology is not known. Using a proof of contradiction argument, lack of GQ1b serves as the indirect proof that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is probably the infection preceding demyelination. A novel antigen has yet to be described. 
format Online
Article
Text
id pubmed-7779142
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-77791422021-01-05 Miller Fisher Syndrome in the COVID-19 Era – A Novel Target Antigen Calls for Novel Treatment Kajani, Surina Kajani, Raheem Huang, Chin-Wei Tran, Tu Liu, Antonio K Cureus Neurology Although Miller Fisher syndrome cases have been published in this coronavirus disease 2019 (COVID-19) pandemic, anti-GQ1b antibody has not been identified so far. A direct proof of association is not yet available since the exact pathophysiology is not known. Using a proof of contradiction argument, lack of GQ1b serves as the indirect proof that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is probably the infection preceding demyelination. A novel antigen has yet to be described.  Cureus 2021-01-01 /pmc/articles/PMC7779142/ /pubmed/33409112 http://dx.doi.org/10.7759/cureus.12424 Text en Copyright © 2021, Kajani et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Neurology
Kajani, Surina
Kajani, Raheem
Huang, Chin-Wei
Tran, Tu
Liu, Antonio K
Miller Fisher Syndrome in the COVID-19 Era – A Novel Target Antigen Calls for Novel Treatment
title Miller Fisher Syndrome in the COVID-19 Era – A Novel Target Antigen Calls for Novel Treatment
title_full Miller Fisher Syndrome in the COVID-19 Era – A Novel Target Antigen Calls for Novel Treatment
title_fullStr Miller Fisher Syndrome in the COVID-19 Era – A Novel Target Antigen Calls for Novel Treatment
title_full_unstemmed Miller Fisher Syndrome in the COVID-19 Era – A Novel Target Antigen Calls for Novel Treatment
title_short Miller Fisher Syndrome in the COVID-19 Era – A Novel Target Antigen Calls for Novel Treatment
title_sort miller fisher syndrome in the covid-19 era – a novel target antigen calls for novel treatment
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779142/
https://www.ncbi.nlm.nih.gov/pubmed/33409112
http://dx.doi.org/10.7759/cureus.12424
work_keys_str_mv AT kajanisurina millerfishersyndromeinthecovid19eraanoveltargetantigencallsfornoveltreatment
AT kajaniraheem millerfishersyndromeinthecovid19eraanoveltargetantigencallsfornoveltreatment
AT huangchinwei millerfishersyndromeinthecovid19eraanoveltargetantigencallsfornoveltreatment
AT trantu millerfishersyndromeinthecovid19eraanoveltargetantigencallsfornoveltreatment
AT liuantoniok millerfishersyndromeinthecovid19eraanoveltargetantigencallsfornoveltreatment

Ejemplares similares